| Combination of | |
|---|---|
| Ipratropium bromide | Muscarinic antagonist |
| Salbutamol | Short-acting β2-adrenergic agonist |
| Clinical data | |
| Trade names | Combivent, DuoNeb, Breva, others |
| AHFS/Drugs.com | Professional Drug Facts |
| MedlinePlus | a601063 |
| License data |
|
| Routes of administration | Inhalation |
| ATC code | |
| Legal status | |
| Legal status | |
| (verify) | |
Ipratropium bromide/salbutamol, sold under the brand name Combivent among others, is a combination medication used to treat chronic obstructive pulmonary disease (COPD).[2][3] It contains ipratropium (an anticholinergic) and salbutamol (albuterol, a β2-adrenergic agonist).[2] It is taken by inhalation.[4]
Common side effects include sore throat, muscle cramps, and nausea.[2] Other side effects may include bronchospasm, allergic reactions, and upper respiratory tract infections.[2] Safety in pregnancy is unclear.[1] Each medication typically decreases bronchospasm and does so via different mechanisms.[2]
The combination was approved for medical use in the United States in 1996.[4] It is available as a generic medication.[3] In 2017, it was the 172nd most commonly prescribed medication in the United States, with more than three million prescriptions.[5][6]
Society and culture
Since Combivent contains a chlorofluorocarbon-based propellant, it is being phased out in European Union countries. Chloroflourocarbons (CFC) are attributed to depletion of the ozone layer.
References
- ^ a b "Albuterol / ipratropium Use During Pregnancy". Drugs.com. Retrieved 19 April 2019.
- ^ a b c d e "DailyMed - ipratropium bromide and albuterol sulfate inhalant". dailymed.nlm.nih.gov. Retrieved 18 April 2019.
- ^ a b British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 247. ISBN 9780857113382.
- ^ a b "Ipratropium and Albuterol - FDA prescribing information, side effects and uses". Drugs.com. Retrieved 18 April 2019.
- ^ "The Top 300 of 2020". ClinCalc. Retrieved 11 April 2020.
- ^ "Albuterol Sulfate; Ipratropium Bromide - Drug Usage Statistics". ClinCalc. Retrieved 11 April 2020.
External links
- DailyMed
- Consumer Medication Information from PubMed
- National Asthma Education and Prevention Program Expert Panel 3. Expert panel report 3: guidelines for the diagnosis and management of asthma. Bethesda (MD): National Institutes of Health. National Heart, Lung, and Blood Institute; 2007 Aug. NIH Publication No. 07-4051.